Echinocandin B Market Size, Shares and Companies
The echinocandin B market was valued at approximately USD 44.60 million in 2023 and is projected to reach USD 79.54 million by 2034, reflecting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2034. This growth is primarily driven by the rising incidence of fungal infections, increased research and development activities, and heightened investments in the sector.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5259
Echinocandin B Market Trends
Recent Acquisitions and Developments
In October 2023, Biosynth announced its acquisition of Pepceuticals, a British manufacturer specializing in synthetic peptides. This acquisition enhances Biosynth’s market position by integrating Pepceuticals’ multi-kilogram Good Manufacturing Practice (GMP) facilities and fill/finish capabilities.
In August 2023, Sandoz acquired the worldwide brand rights for Mycamine (micafungin sodium) from Astellas. This strategic move aims to strengthen Sandoz’s global hospital offerings and enhance its portfolio of anti-infectives. For the fiscal year ending March 31, 2023, Mycamine recorded sales of $105 million.
Growing Research & Development: Unlocking Potential
Echinocandins represent the first class of molecules approved for treating fungal infections, with echinocandin B being a notable variant. The rising interest in natural products as therapeutic agents is driving demand for echinocandins as antifungal treatments. Ongoing research is focused on developing novel derivatives of echinocandins to improve potency and efficacy. Furthermore, innovative drug delivery systems are being explored for the targeted and sustained release of echinocandin B. Researchers are also investigating the potential role of echinocandin B in treating other conditions, including viral disorders. As echinocandin B is extracted via fermentation from the fungus Aspergillus nidulans, novel extraction methods are being developed to streamline this process.
Antimicrobial Resistance: A Challenge for Echinocandin B
A significant challenge facing the echinocandin B market is the emergence of resistance among fungal organisms. Species such as Cryptococcus, Trichosporon, and zygomycetes have shown resistance to echinocandins, while weak activity is noted against the yeast forms of Histoplasma, Blastomyces, and Coccidioides. This resistance diminishes the biological efficacy of echinocandins in humans, limiting their therapeutic application. According to a report by the Centers for Disease Control and Prevention (CDC), echinocandin resistance poses a serious clinical and public health threat, particularly when combined with resistance to azole and amphotericin B.
North America: A Leader in R&D Facilities
In 2023, North America emerged as the dominant market for echinocandin B, driven by its advanced research and development facilities, rising incidence of fungal infections, and growing collaborations. The CDC reports that common fungal diseases in the US include ringworm, nail infections, and vaginal yeast infections. Pharmaceutical companies in the US and Canada are investing between 14% and 50% of their revenues in pharmaceutical R&D, fostering innovation and drug development in the echinocandin B market. The recent approval of rezafungin for treating candidemia and invasive candidiasis further supports market growth, alongside increased investments and the presence of key industry players.
Asia-Pacific: Rapid Market Growth Anticipated
The Asia-Pacific region is expected to experience the fastest growth in the echinocandin B market during the forecast period. Key factors driving this growth include a rising geriatric population, increasing fungal infection rates, and expanding research and development initiatives. In 2023, China reported around 182 hospitalizations and outbreaks associated with Candida auris, a significant increase from 33 in 2022. In India, fungal diseases affect over 57 million people annually, heightening the demand for novel echinocandin B analogs. The region’s favorable manufacturing infrastructure and growing investments, along with an increase in clinical trials and patents, are also expected to contribute to market growth.
Top Companies in the Echinocandin B Market
- Aquigen BioScience
- Biosynth
- Cayman Chemical
- Cidara Therapeutics
- Chemicea Pharmaceuticals Pvt. Ltd.
- GlaxoSmithKline, plc.
- Glenmark Pharmaceuticals Ltd.
- Hubei Chenxin Pharmaceutical Co. Ltd.
- MedChemExpress
- Melinta Therapeutics
- Mylan N.V.
- Novartis
- Santa Cruz Biotechnology
- Shanghai Yuanye Biotechnology Co. Ltd.
- TOKU-E Corporation
- VWR, Inc.
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/echinocandin-b-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5259
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Visit Dental Specifics: https://www.towardsdental.com
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
